Citizens Reiterates Market Outperform on CRISPR Therapeutics, Maintains $80 Price Target

Benzinga · 1d ago
Citizens analyst Silvan Turkcan reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Market Outperform and maintains $80 price target.